Newsletter | September 15, 2021

09.15.21 -- The Human Touch Of Decentralized Clinical Trials

The Human Touch Of Decentralized Clinical Trials

When we talk about decentralized clinical trials (DCTs), the conversation usually centers on the technology; however, DCTs require more than technology. There is an equally important human component driven by specialized study teams who engage patients where they live. Learn how mobile research teams have become the unsung heroes of the tech-enabled clinical trials movement.

Patient-Centricity By Design

When healthcare centers shut down during the COVID-19 pandemic, sponsors relied on decentralized clinical trials (DCTs) to keep patients and staff safe, while continuing to move research forward. In making this transition they discovered additional benefits of DCTs that take patient preferences and needs into consideration and include connected devices to drive greater efficiency and engagement.

Can Decentralized Clinical Trials Solve Attrition? Early Research Suggests ‘Yes.’

Patient attrition has always been a challenge in clinical research, but the use of decentralized clinical trials may help sponsors overcome attrition problems. Learn what clinical trial models can bolster retention and greater engagement between patients, investigators, and sponsors.

Overcoming Pharma’s Diversity Problem

Sponsors have discovered that it is not easy to assemble a perfectly diverse patient population that also meets all inclusion/exclusion criteria. Facing the simultaneous pressure to lower costs and accelerate timelines, diversity goals can often slide down the priority list. However, the growing adoption of decentralized clinical trials may now help make recruiting diverse, representative groups of participants more achievable.

China Embraces Decentralized Clinical Trial Solutions

The biopharmaceutical industry in China, like the rest of the world, was forced to swiftly adopt decentralized clinical trial approaches to maintain progress during the COVID-19 pandemic. And, like the rest of the world, its patients, investigators, and sponsors were hopeful about the benefits of using these tools. Surveys show that patients, sponsors, and CROs in China see the benefits of virtual and hybrid trials.